Cargando…

MCC950 closes the active conformation of NLRP3 to an inactive state

NLRP3 is an innate immune sensor contributing to the development of different diseases including monogenic autoinflammatory syndromes, gout, atherosclerosis, and Alzheimer’s disease. The molecule sulfonylurea MCC950 is a NLRP3 inflammasome inhibitor with potential clinical utility. However, the mech...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tapia-Abellán, Ana, Angosto-Bazarra, Diego, Martínez-Banaclocha, Helios, de Torre-Minguela, Carlos, Cerón-Carrasco, Jose P., Pérez-Sánchez, Horacio, Arostegui, Juan I., Pelegrin, Pablo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7116292/ https://www.ncbi.nlm.nih.gov/pubmed/31086329 http://dx.doi.org/10.1038/s41589-019-0278-6

Ejemplares similares

Targeting the NLRP3 Inflammasome With Inhibitor MCC950 Prevents Aortic Aneurysms and Dissections in Mice
por: Ren, Pingping, et al.
Publicado: (2020)

Physiological and pathophysiological functions of NLRP6: pro- and anti-inflammatory roles
por: Angosto-Bazarra, Diego, et al.
Publicado: (2022)

Inhibiting the NLRP3 Inflammasome Activation with MCC950 Ameliorates Diabetic Encephalopathy in db/db Mice
por: Zhai, Yadong, et al.
Publicado: (2018)

The selective NLRP3 inhibitor MCC950 hinders atherosclerosis development by attenuating inflammation and pyroptosis in macrophages
por: Zeng, Wenyun, et al.
Publicado: (2021)

MCC950, the NLRP3 Inhibitor, Protects against Cartilage Degradation in a Mouse Model of Osteoarthritis
por: Ni, Bowei, et al.
Publicado: (2021)

Selective NLRP3 Inflammasome Inhibitor MCC950 Suppresses Inflammation and Facilitates Healing in Vascular Materials
por: Grant, Angus J., et al.
Publicado: (2023)

Sensing low intracellular potassium by NLRP3 results in a stable open structure that promotes inflammasome activation
por: Tapia-Abellán, Ana, et al.
Publicado: (2021)

Inhibiting the NLRP3 Inflammasome With MCC950 Ameliorates Isoflurane-Induced Pyroptosis and Cognitive Impairment in Aged Mice
por: Fan, Yunxia, et al.
Publicado: (2018)

The Small Molecule NLRP3 Inflammasome Inhibitor MCC950 Does Not Alter Wound Healing in Obese Mice
por: Lee, James S., et al.
Publicado: (2018)

Adverse renal effects of NLRP3 inflammasome inhibition by MCC950 in an interventional model of diabetic kidney disease
por: Østergaard, Jakob A., et al.
Publicado: (2022)

NLRP3 lacking the leucine-rich repeat domain can be fully activated via the canonical inflammasome pathway
por: Hafner-Bratkovič, Iva, et al.
Publicado: (2018)

A Probe for NLRP3 Inflammasome Inhibitor MCC950 Identifies Carbonic Anhydrase 2 as a Novel Target
por: Kennedy, Cassandra R., et al.
Publicado: (2021)

MCC950 ameliorates ventricular arrhythmia vulnerability induced by heart failure
por: Jiang, Xiaobo, et al.
Publicado: (2022)

MCC950, a specific small molecule inhibitor of NLRP3 inflammasome attenuates colonic inflammation in spontaneous colitis mice
por: Perera, Agampodi Promoda, et al.
Publicado: (2018)

A small molecule inhibitor MCC950 ameliorates kidney injury in diabetic nephropathy by inhibiting NLRP3 inflammasome activation
por: Zhang, CongXiao, et al.
Publicado: (2019)

NLRP3 inflammasome inhibitor MCC950 can reduce the damage of pancreatic and intestinal barrier function in mice with acute pancreatitis
por: Shen, Yanghui, et al.
Publicado: (2022)

NLRP3 Inflammasome and Pyroptosis in Liver Pathophysiology: The Emerging Relevance of Nrf2 Inducers
por: Hurtado-Navarro, Laura, et al.
Publicado: (2022)

MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition
por: Vande Walle, Lieselotte, et al.
Publicado: (2019)

Inhibiting the inflammasome with MCC950 counteracts muscle pyroptosis and improves Duchenne muscular dystrophy
por: Dubuisson, Nicolas, et al.
Publicado: (2022)

Intraperitoneal Injection of MCC950 Inhibits the Progression of Myopia in Form-Deprivation Myopic Mice
por: Chen, Zhengyu, et al.
Publicado: (2023)

Inhibition of NLRP3 inflammasome by MCC950 improves the metabolic outcome of islet transplantation by suppressing IL-1β and islet cellular death
por: Matsuoka, Taisuke, et al.
Publicado: (2020)

NLRP3 inflammasome inhibitor MCC950 attenuates primary dysmenorrhea in mice via the NF-κB/COX-2/PG pathway
por: Tang, Biao, et al.
Publicado: (2020)

Correction: MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition
por: Walle, Lieselotte Vande, et al.
Publicado: (2019)

Blockage of KHSRP-NLRP3 by MCC950 Can Reverse the Effect of Manganese-Induced Neuroinflammation in N2a Cells and Rat Brain
por: Singh, Sharad, et al.
Publicado: (2022)

P2X7 receptor induces mitochondrial failure in monocytes and compromises NLRP3 inflammasome activation during sepsis
por: Martínez-García, Juan José, et al.
Publicado: (2019)

Protection of Mcc950 against high-glucose-induced human retinal endothelial cell dysfunction
por: Zhang, Yi, et al.
Publicado: (2017)

MCC950, a Selective Inhibitor of NLRP3 Inflammasome, Reduces the Inflammatory Response and Improves Neurological Outcomes in Mice Model of Spinal Cord Injury
por: Jiao, Jianhang, et al.
Publicado: (2020)

MCC950, a Selective NLRP3 Inhibitor, Attenuates Adverse Cardiac Remodeling Following Heart Failure Through Improving the Cardiometabolic Dysfunction in Obese Mice
por: Wang, Menglong, et al.
Publicado: (2022)

Normothermic ex vivo heart perfusion with NLRP3 inflammasome inhibitor Mcc950 treatment improves cardiac function of circulatory death hearts after transplantation
por: Xu, Liwei, et al.
Publicado: (2023)

The Selective NLRP3-inflammasome inhibitor MCC950 Mitigates Post-resuscitation Myocardial Dysfunction and Improves Survival in a Rat Model of Cardiac Arrest and Resuscitation
por: Zheng, Guanghui, et al.
Publicado: (2022)

The NLRP3 and Pyrin Inflammasomes: Implications in the Pathophysiology of Autoinflammatory Diseases
por: de Torre-Minguela, Carlos, et al.
Publicado: (2017)

MCC950 Ameliorates Acute Liver Injury Through Modulating Macrophage Polarization and Myeloid-Derived Suppressor Cells Function
por: Yan, Wei, et al.
Publicado: (2021)

CD14 release induced by P2X7 receptor restricts inflammation and increases survival during sepsis
por: Alarcón-Vila, Cristina, et al.
Publicado: (2020)

MCC950, a selective NLPR3 inflammasome inhibitor, improves neurologic function and survival after cardiac arrest and resuscitation
por: Jiang, Maorong, et al.
Publicado: (2020)

Inhibiting the NLRP3 inflammasome with MCC950 ameliorates retinal neovascularization and leakage by reversing the IL-1β/IL-18 activation pattern in an oxygen-induced ischemic retinopathy mouse model
por: Sui, Ailing, et al.
Publicado: (2020)

Techniques to Study Inflammasome Activation and Inhibition by Small Molecules
por: Angosto-Bazarra, Diego, et al.
Publicado: (2021)

Combined Therapy With Polyethylene Glycol‐20k and MCC950 Preserves Post‐Resuscitated Myocardial Function in a Rat Model of Cardiac Arrest and Cardiopulmonary Resuscitation
por: Liang, Lian, et al.
Publicado: (2021)

Evolutionary analyses of the gasdermin family suggest conserved roles in infection response despite loss of pore-forming functionality
por: Angosto-Bazarra, Diego, et al.
Publicado: (2022)

When Virtual Screening Yields Inactive Drugs: Dealing with False Theoretical Friends
por: Cerón‐Carrasco, José P.
Publicado: (2022)

The binding of Varp to VAMP7 traps VAMP7 in a closed, fusogenically inactive conformation
por: Schäfer, Ingmar B., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_vq3iea9gomlfa2it7qdh2r4g25